Mandate

Vinge is advising Xspray Pharma in connection with its rights issue

December 03, 2024 Capital Markets and Public M&A

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Joel Magnusson, Adrian Filipovic and Elias Kröger.

Related

Vinge advises DNB Carnegie in connection with a EUR 130 million bond issue to finance Incore Invest’s acquisition of CoreOrchestration

Vinge has advised DNB Carnegie Investment Bank AB (publ), in its capacity as sole bookrunner, in connection with an issue of senior secured bonds of EUR 130 million under a framework of EUR 200 million.
February 16, 2026

Vinge has advised BAE Systems Bofors on the acquisition of Aston Harald Mekaniska Verkstad

BAE Systems is a world-leading defence group with a presence in Sweden through, among others, BAE Systems Bofors in Karlskoga, a supplier of weapon systems, artillery and ammunition. The acquisition is strategically motivated and aims to strengthen the Swedish defence industry's production capacity.
February 12, 2026

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026